GlassScriptPhysician profile
Barbara Anne Lowry
NPI 1841374337
$5,429.35
in general payments reported to CMS, 2019-2025
26 companies · $740 in 2025
The $740 reported for 2025 was more than what 77% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,371 · 2020: $737 · 2021: $905 · 2022: $419 · 2023: $358 · 2024: $899 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,997.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $806.56 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $693.65 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $601.73 | 2019-2022 | |
| Lundbeck LLC | $573.04 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $512.08 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $464.86 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $233.63 | 2019-2025 | Trintellix |
| Allergan, INC. | $223.68 | 2020 | |
| Neos Therapeutics, LP | $147.97 | 2019-2024 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $141.58 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $123.92 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.66 | 2020-2025 | Caplyta |
| Eisai INC. | $110.38 | 2020-2021 | |
| Almatica Pharma LLC | $109.44 | 2023-2024 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $98.03 | 2023-2024 | Quviviq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $97.53 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $64.05 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $53.80 | 2021 | |
| Vanda Pharmaceuticals INC. | $49.82 | 2019-2025 | Fanapt, Hetlioz |
| Shire North American Group INC | $39.50 | 2019 | |
| Jazz Pharmaceuticals INC. | $37.78 | 2019 | |
| Tris Pharma INC | $34.99 | 2020-2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $34.59 | 2025 | Jornay Pm |
| Corium, LLC | $21.49 | 2024 | Azstarys |
| Adlon Therapeutics L.P. | $16.64 | 2020 | |
| Vertical Pharmaceuticals, LLC | $15.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Lowry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.